Texas Senate Health Committee Interim Report on COVID-19 | Robert W Malone MD, MS

Treatment Policies, Regulatory Guidance, and Patient Care

Some readers and listeners may recall that I testified at the behest of the Texas Senate Health and Human Services Committee Hearing on June 27, 2022 regarding the COVID crisis, public health response and the vaccines.. My prepared remarks which were presented at that time can be found at this Substack link.

During this testimony. I was asked to specifically comment on Treatment Policies, Regulatory Guidance, and Patient Care, with a particular focus on the capacity for infectious disease control services provided in the state of Texas. The objective was to ensure that the state has transparent, data-driven recommendations on public health matters; and to consider establishing an independent, transparent state-based regulatory authority for developing and distributing disease treatment.

As of today, the report generated from this testimony has now been made available for public review.

For the section regarding Treatment Policies, Regulatory Guidance, and Patient Care, the Texas State Senate Health and Human Services Interim Report general recommendations are as follows:

  • Assess the capacity by which infectious disease control services are provided in Texas. Ensure the state has transparent, data-driven recommendations on public health matters; and consider establishing an independent, transparent state-based regulatory authority for developing and distributing disease treatment.
  • Examine statutory changes to ensure patients have access to prescriptions submitted by licensed physicians in Texas related to COVID-19;
  • Prohibit future mask mandates;
  • Prohibit COVID-19 vaccine mandates and maintain that vaccines remain voluntary;
  • Form a special committee/working group on medical censorship; and
  • Establish a grant program accessible to Texas-based independent entities to conduct research on the adverse events of the COVID-19 vaccines directly associated with vaccine use.


The specific report section entitled “Treatment Policies, Regulatory Guidance, and Patient Care” reads as follows:

Treatment Policies, Regulatory Guidance, and Patient Care

(References are in the original document)

Throughout the early variant surges during the pandemic, various early treatment options emerged including hydroxychloroquine, ivermectin, Paxlovid, plasma infusions, and the use of steroids. Yet, there was little effort by agencies to catalog patients according to treatments received (15).

In most cases, the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) have been the primary decision-makers in terms of treatment policy and guidelines during the COVID-19 pandemic with little input from independent and or practicing physicians (16). Multiple studies submitted by physicians across the country have shown through the use of early treatment options there is a 95% reduction rate in hospitalization and death among those infected (17). Data reflecting the success rate of early treatment of the virus provide a potential blueprint for future outbreaks and infectious disease responses (18).

Instead, federal guidance, and subsequent guidance from DSHS, touted the need for mass vaccination against COVID-19. Little to no data on early treatment efficacy were collected from hospitalized patients, making effective treatments difficult to track(19). The use of early treatment measures varied according to federal guidelines and hospital policy (20). With the extension of Emergency Use Authorizations (EUAs) for the COVID-19 vaccines, the development of repurposed drugs and other strategies to combat the virus have been blocked by NIH and the Food and Drug Administration (FDA) due to requirements within the statutory language of EUAs (21).

Current numbers place the antibody rate for the state of Texas at 98%. (22). The rate is considered a combination of prior COVID-19 infections and vaccinated individuals. Despite the high antibody rate, and other factors associated with natural immunity, some hospitals continued to require vaccinations for employees.

When COVID-19 vaccine requirements for employees were first implemented, the initial understanding was immunity from vaccinations was much stronger than natural immunity, yet new information currently calls that understanding into question. Current data demonstrate that the vaccine has only reduced 20-30% of hospitalizations and deaths (23). With Omicron and its subvariants becoming the dominant strain, the evolution of the spike protein within the virus raises concern for the future efficacy of the vaccine along with the onset of immune imprinting (24). According to Dr. Robert Malone, immune imprinting occurs following a prior infection with the original COVID-19 strain, followed by vaccinations, and reinfection with Omicron which reveals a paradox in a reduction in neutralizing antibodies among an estimated 30% of the immunocompromised (25). This leads to a relatively selective immune deficiency leaving the specific population with a higher chance of chronic reinfection (26). Data from Lessons from COVID-19 suggests continual boosting exacerbates the reinfection rate, particularly due to the focus on the spike protein which has a high rate of mutation (27).

Additionally, the push for the expediency of the vaccine resulted in agencies bypassing long- standing clinical and nonclinical trial protocols (28). Vaccine trials failed to follow the normal process for clinical observations of at least 24 months with COVID-19 observational trials lasting two months (29). The vaccines remain listed as Emergency Use Authorization Investigative, which means they are unsure as to what adverse events may occur after a person receives the shot (30). As of June 2022, the CDC’s VAERS data system, which catalogs adverse events from vaccines, reported 13,388 deaths in the United States associated with the COVID-19 vaccine (31). Worldwide, the largest vaccine databases have reported 40,000 deaths associated with the vaccine (32). According to Dr. McCullough, in less than one year the polio vaccine was recalled after 10 reported deaths, and the swine flu vaccine was recalled after 53 deaths (33). Yet no legislative body within the U.S. federal or state government has acted upon a global call to recall vaccines from the market following 28,000 reported associated deaths (34).

For patients, some hospital officials have reported they were treated regardless of vaccination status (35).3 During the Omicron surge, patients were tested before entry/treatment but were not denied treatment based on test results (36). Some reports indicated during the pandemic individuals were denied treatment due to their vaccination status (37). However, there are no data to determine if it was widespread or simply an isolated event. In the case of many hospitals in Texas, treatment protocols and infection mitigation were based on CDC and NIH guidance.*

Listen to audio and continue reading on Source: Texas Senate Health Committee Interim Report on COVID-19